Citation:Örnek N,Örnek K,Aydin S,Yilmaz M,Ölmez Y.Serum vascular endothelial growth factor receptor-2 and adropin levels in age-related macular degeneration.Int J Ophthalmol 2016;9(4):556-560,doi:10.18240/ijo.2016.04.13
Serum vascular endothelial growth factor receptor-2 and adropin levels in age-related macular degeneration
Received:May 01, 2015  Revised:July 20, 2015
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2016.04.13
Key Words:vascular endothelial growth factor receptor-2; adropin; age-related macular degeneration
Fund Project:
              
AuthorInstitution
Nurgül Örnek Department of Ophthalmology, School of Medicine, Kirikkale University, Kirikkale 71450, Turkey
Kemal Örnek Department of Ophthalmology, School of Medicine, Kirikkale University, Kirikkale 71450, Turkey
Süleyman Aydin Department of Biochemistry, School of Medicine, Firat University, Elazig 23300, Turkey
Musa Yilmaz Department of Biochemistry, School of Medicine, Firat University, Elazig 23300, Turkey
Yaşar Ölmez Department of Ophthalmology, School of Medicine, Kirikkale University, Kirikkale 71450, Turkey
Hits: 630
Download times: 116
Abstract:
      AIM: To investigate the serum levels of vascular endothelial growth factor receptor-2 (VEGFR-2) and adropin in age-related macular degeneration (AMD) patients.

    METHODS: Ninety-eight AMD patients were included in the study. Seventy-eight age- and sex-matched healthy volunteers were recruited as the control group. Fundus florescein angiography and optical coherence tomography were performed to assess the posterior segment details. Serum VEGFR-2 and adropin levels were measured using enzyme-linked immunosorbent assays and compared between the study groups.

    RESULTS: AMD group had significantly increased foveal retinal thickness, serum LDL and HDL levels and significantly decreased subfoveal choroidal thickness (P =0.01, 0.047, 0.025 and <0.001, respectively). Serum VEGFR-2 level revealed a significant decrease in AMD patients compared to controls (26.48±6.44 vs 30.42±7.92 ng/mL, P<0.001). There was an insignificant increase in serum adropin level in AMD patients (6.17±3.19 vs 5.79±2.71 ng/mL, P=0.4) . Serum level of VEGFR-2 in AMD patients had a significant negative correlation with foveal retinal thickness (r=-0.226, P=0.025) and a significant positive correlation with subfoveal choroidal thickness (r=0.2, P=0.048).

    CONCLUSION: The current study demonstrated that the decreased serum VEGFR-2 level may be considered in the development of AMD. Adropin does not seem to play a role in the pathogenesis of AMD.

PMC FullText Html:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853351/
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment